Released on 2019-03-16Categories Business & Economics

Biotechnology Valuation & Investing

Biotechnology Valuation & Investing

Author: Jason Hsu

Publisher: Independently Published

ISBN: 1790407486

Category: Business & Economics

Page: 166

View: 229

The selection of biotech stocks for investment is more difficult compared with the selection of other stocks and industries that possess historical data, since biotechnology is a recently new science. In the first edition of this book, we described the crucial parameters for the valuation of an early stage biotech company without a drug in the market. In this edition, we analyze novel financial models that can value stocks of biotech companies with products in the market or products under development (in pre-clinical and clinical studies). All of these parameters should be helpful to potential new investors when creating a stock portfolio that includes highly promising biotech companies. Our strategy of selecting highly promising stocks based on all parameters described in this book and of performing a basic financial modeling analysis with DFC and/or real options valuation models has proven very successful, as this strategy provides returns higher than 100% in most cases. In the first edition of this book, based on our strategy, we suggested that Juno Therapeutics and Kite Pharma were "hot" stocks. At that time, Kite's stock was $50.19, while Juno's stock was $54.21. Since then, Kite's stock reached $179.79, with the company acquired by Gilead for $11.9 billion, while Juno's stock reached $86.96, with the company acquired by Celgene for $9 billion. Furthermore, Moderna Therapeutics, a private company that we valued at $5.5 billion in 2016 based on our real options financial model, today has a $7.5 billion valuation. This newly revised and expanded version was written to help investors in the selection of biotech stocks based on different scientific and financial criteria.
Released on 2009-01-15Categories Business & Economics

Biotechnology Valuation

Biotechnology Valuation

Author: Karl Keegan

Publisher: John Wiley & Sons

ISBN: 9780470741344

Category: Business & Economics

Page: 216

View: 517

The first book to provide a simple and practical means of valuing biotech companies The book begins with a short history of the biotechnology industry; this is important as although it is about 30 years old, the first company went public only in 1996, so it is possible to plot the course of investment waves and dips It examines the European industry and its evolvement, and draws parallels between the similarities and differences between that and the US Looks at the various companies which make up the biotech industry (therapeutic; life sciences; and the medical technology company) and gives tools for the investor to properly evaluate them Praise for Biotechnology Valuation "Keegan states that the valuation of Biotech companies is as much an art as a science. This brief but comprehensive review of the skills and knowledge required, not of just the financial market and sentiment, but also of the technical attributes of a company and the drug development and regulatory hurdles that must be overcome, highlights the importance of the breadth of understanding required. Biotech investing is not for the timid, but it can bring substantial returns. Keegan's book, punctuated with his personal experience and opinions, is a good place to start." —Chris Blackwell, Chief Executive, Vectura Group plc "A user-friendly, yet thorough discussion of a notoriously difficult topic. Dr Keegan's book is a fine resource for both business types and academicians." —Steve Winokur, Managing Director, CanaccordAdams "A highly readable and comprehensive explanation of the technical and commercial parameters that influence biotechnology companies at all stages of development, providing clear context for selection from the toolkit of valuation methodologies the author recommends to assess company and product performance, or ascribe value." —Dr L.M. Allan, Director, Bioscience Enterprise Programme, University of Cambridge "A fabulous approach to a difficult topic." —Deirdre Y. Gillespie, MD, President & CEO, La Jolla Pharmaceutical Company
Released on 2002Categories Business & Economics

The Essential Biotech Investment Guide

The Essential Biotech Investment Guide

Author: Chilung Mark Tang

Publisher: World Scientific

ISBN: 9812381392

Category: Business & Economics

Page: 296

View: 911

This invaluable book tells the reader how to invest in the healthcare biotechnology and life sciences sector, one of the fast-growing sectors of the US economy. Aimed at biotech investors as well as bioentrepreneurs and venture capitalists, it has been written from the perspectives of risk management and asset management/allocation. It strives to teach readers how to fish, rather than giving them fish. The author has over ten years of Wall Street experience in biotech research, investment banking and asset management. He holds an MBA in Finance and a PhD in Biochemistry.
Released on 2001-06-13Categories Business & Economics

The Biotech Investor's Bible

The Biotech Investor's Bible

Author: George Wolff

Publisher: John Wiley & Sons

ISBN: 0471412791

Category: Business & Economics

Page: 374

View: 225

A one-stop source for investing in biotech-with detailed coverage of the science, the business, the players, and the strategies for one of today's most promising (and volatile) industries To invest in biotech is to invest in the future, and as such, investors need to learn the nuances of the science they're putting their money on. The core asset of biotech companies is knowledge, and sound investment decisions are impossible without an understanding of this complex science. That's where The Biotech Investor's Bible fits in. This much-needed, one-of-a-kind resource simplifies the complex science surrounding the business of biotech and clarifies subtle distinctions within the context of their financial repercussions. The book explains the basics of genetics, patents, and therapies; and teaches investors how to value biotech companies and their state-of-the art products and technology. The Biotech Investor's Bible offers an informative summary of the relatively short history of the industry and provides a comprehensive review of various industry sectors.
Released on 2014-10-31Categories Business & Economics

Valuation in Life Sciences

Valuation in Life Sciences

Author: Boris Bogdan

Publisher: Springer

ISBN: 3642425844

Category: Business & Economics

Page: 370

View: 506

Valuation is a hot topic among life sciences professionals. There is no clear understanding on how to use the different valuation approaches and how to determine input parameters. Some do not value at all, arguing that it is not possible to get realistic and objective numbers out of it. Some claim it to be an art. In the following chapters we will provide the user with a concise val- tion manual, providing transparency and practical insight for all dealing with valuation in life sciences: project and portfolio managers, licensing executives, business developers, technology transfer managers, entrep- neurs, investors, and analysts. The purpose of the book is to explain how to apply discounted cash flow and real options valuation to life sciences p- jects, i.e. to license contracts, patents, and firms. We explain the fun- mentals and the pitfalls with case studies so that the reader is capable of performing the valuations on his own and repeat the theory in the exercises and case studies. The book is structured in five parts: In the first part, the introduction, we discuss the role of the players in the life sciences industry and their p- ticular interests. We describe why valuation is important to them, where they need it, and the current problems to it. The second part deals with the input parameters required for valuation in life sciences, i.e. success rates, costs, peak sales, and timelines.
Released on 2010-12-30Categories Business & Economics

The Triumph of Value Investing

The Triumph of Value Investing

Author: Janet Lowe

Publisher: Penguin

ISBN: 9781101475218

Category: Business & Economics

Page: 240

View: 890

Timely advice from value-investing giants such as Warren Buffett, William O'Neil, Charles Brandes, and David Iben. After the financial chaos and panic of the last few years, investors are looking to rebuild confidence and learn from the mistakes that led to the crash. In The Triumph of Value Investing, Janet Lowe urges readers to return to the basic principles of value investing as taught by the legendary Benjamin Graham, which remain just as relevant today. These lessons can help readers maneuver sanely through any type of economic turmoil and even benefit from further disruptions. Lowe also includes interviews with leading value investors such as Warren Buffett, William O'Neil, and Charles Brandes, and analyzes dozens of U.S. and foreign stocks. She walks investors through the steps necessary to apply the principles that define value investing, with special emphasis on investing in biotech, high-technology, and foreign companies. Whether readers are familiar with value investing or are just discovering it, they will find plenty of fresh information in The Triumph of Value Investing, which covers the latest concepts and players in the market. As Lowe writes, "It is always healthy to check up on the validity of your own thinking. Considering the market breakdowns of the past decade and the confusion and discouragement many individual investors have suffered, this is an excellent time to restudy Benjamin Graham's concepts of value investing and learn how to apply them to a whole range of new challenges."
Released on 2008-02Categories

Financing in Life Sciences Biotech Companies

Financing in Life Sciences Biotech Companies

Author: Christian Strassburger

Publisher: GRIN Verlag

ISBN: 9783638903431

Category:

Page: 89

View: 687

Seminar paper from the year 2006 in the subject Business economics - Investment and Finance, grade: 1,3, Pforzheim University, course: Corporate Finance, 25 entries in the bibliography, language: English, abstract: Biotechnology is a more and more important field of research in present. Publicly we are currently confronted with many questions about the rights and wrongs within this field of science, like how to handle the issue of gene manipulation or stem cell research. However, biotechnology is more than just an accumulation of ethical questions and science - it is a whole industry and as such interesting for investors. The scope of this paper is not dealing with the topics discussed in glossy magazines, but it addresses the issues of corporate finance in biotechnology. In order to get an overview of the industry from a finance point of view, the industry has to be portrayed. Hence, this is the topic of chapter two. From the point of the investors, and therefore of the capital markets, the understandability of the segment biotechnology, and thus the availability of crucial information has to be ensured. Consequently the transparency of the biotechnology segment and of the individual enterprises, respectively, are the topics of the third chapter. The implications of this chapter have a strong impact on the valuation of biotechnological companies and the sector as a whole - a subject dealt with in chapter number four. The fifth chapter is concerned with the core topic of this paper and identifies and analyses different sources of finance for biotechnology enterprises. Thereby it is taking the point of view of the biotechnology firms and the potential investors. The paper is showing important difficulties and advantages connected with the different approaches. Additionally the chapter also describes and evaluates the risks of different options of investors. The paper is concluded with a summary of the findings in chapter six showing that investing into biotechno
Released on 2003-04-07Categories Business & Economics

Real Options in Practice

Real Options in Practice

Author: Marion A. Brach

Publisher: John Wiley & Sons

ISBN: 9780471445562

Category: Business & Economics

Page: 385

View: 504

Explores real option theory applied in practice Real options are quickly becoming the valuation and decision-making method of choice for many companies, including oil and gas companies, utilities and natural resource companies, pharmaceutical and biotech companies, Internet companies, and many others. Real Options in Practice allows readers to view the world of real options from the vantage point of a corporate practitioner applying real option valuation techniques on a regular basis. Expert Marion Brach describes the challenges of implementing a real option framework in practice within a corporate setting. Touching on the real options most firms care about, Real Options in Practice identifies the classic types of real options-deferral, abandonment, switching, expansion, and compound-and explores the main concepts critical to understanding real option theory. Through Brach's own three-step real option valuation method readers will learn how the theory of real options is now being applied to drive better, more profitable corporate decision-making. Marion A. Brach, MD, MBA (Hagen, Germany), has undertaken financial valuation of business opportunities and acquisitions using scenario and real option valuation in the biotech industry. A recognized expert on real option theory and practice, Brach received her MBA from the Manchester Business School and frequently speaks at real option seminars.
Released on 2002-12-02Categories Business & Economics

Essential Biotech Investment Guide, The: How To Invest In The Healthcare Biotechnology And Life Sciences Sector

Essential Biotech Investment Guide, The: How To Invest In The Healthcare Biotechnology And Life Sciences Sector

Author: Tang Mark Chilung

Publisher: World Scientific

ISBN: 9789814487641

Category: Business & Economics

Page: 282

View: 739

This invaluable book tells the reader how to invest in the healthcare biotechnology and life sciences sector, one of the fast-growing sectors of the US economy. Aimed at biotech investors as well as bioentrepreneurs and venture capitalists, it has been written from the perspectives of risk management and asset management/allocation. It strives to teach readers how to fish, rather than giving them fish. The author has over ten years of Wall Street experience in biotech research, investment banking and asset management. He holds an MBA in Finance and a PhD in Biochemistry.
Released on 2008-12-17Categories Science

Biotech Funding Trends

Biotech Funding Trends

Author: Alexandra Carina Gruber

Publisher: John Wiley & Sons

ISBN: 9783527622740

Category: Science

Page: 210

View: 916

Based on interviews with successful biotech entrepreneurs and high-level investors as well as case studies, this title provides a comprehensive overview of current trends in biotech funding. In particular, it illustrates the tensions between both sides based on their different backgrounds and expectations. The book outlines the various funding opportunities for the biotech industry and identifies ways for both sides to overcome their existing prejudices in order to successfully thrive in a competitive environment. A must-have for biotech entrepreneurs and investors, as well as invaluable supplementary reading for students aspiring to a career in the industry.
Released on 2017-01-06Categories Business & Economics

The Pharmagellan Guide to Biotech Forecasting and Valuation

The Pharmagellan Guide to Biotech Forecasting and Valuation

Author: Frank S. David

Publisher: Pharmagellan, LLC

ISBN: 099840750X

Category: Business & Economics

Page: 138

View: 502

If you're a biotech executive, investor, deal maker, entrepreneur, or adviser-or aspire to be one-then you need to know how to build and analyze forecasts and valuation models of R&D-stage drugs. The Pharmagellan Guide is a comprehensive, thoroughly referenced handbook for early-stage biopharma assets and companies.